MaxCyte (NASDAQ:MXCT) 报告称季度每股亏损$(0.10)，高于分析师一致预期的$(0.12)，超出16.67%。这与去年同期每股亏损$(0.05)相比下降了100%。 公司报告季度销售额为$869.3万美元，高于分析师一致预期的$799.3万美元，超出8.76%。这与去年同期销售额$1566.6万相比下降了44.51%。

以上内容来自Benzinga Earnings专栏，原文如下：

MaxCyte (NASDAQ:MXCT) reported quarterly losses of $(0.10) per share which beat the analyst consensus estimate of $(0.12) by 16.67 percent. This is a 100 percent decrease over losses of $(0.05) per share from the same period last year. The company reported quarterly sales of $8.693 million which beat the analyst consensus estimate of $7.993 million by 8.76 percent. This is a 44.51 percent decrease over sales of $15.666 million the same period last year.